Are drugs really toxic for older people?

abstract：OBJECTIVE:The aim of this study was to investigate whether the use of statins was associated with breast cancer risk. BACKGROUND:Experimental studies have shown that statins have potential protective effects against cancer. METHODS:We conducted a population-based case-control study in Taiwan. Cases consisted of all p...

journal_title：Expert opinion on drug safety

authors： Chan TF,Wu CH,Lin CL,Yang CY

更新日期：2014-03-01 00:00:00

abstract：:It is estimated that over three-quarters of a million people are injured or die in hospitals each year from adverse drug events (ADEs). The majority of medical errors result from poorly designed healthcare systems rather than from negligence on the part of healthcare providers. In general, healthcare systems rely on v...

journal_title：Expert opinion on drug safety

authors： Anderson JG

更新日期：2004-09-01 00:00:00

abstract：:An unprecedented interest in biomarker development has arisen from the increasing use of genomic information and high-throughput technologies in the field of drug development. Monitoring global cellular responses to perturbation due to disease, drug treatment or toxicity is achieved using molecular profiling methods s...

journal_title：Expert opinion on drug safety

authors： Bailey WJ,Ulrich R

更新日期：2004-03-01 00:00:00

abstract：INTRODUCTION:Clozapine was first introduced as an antipsychotic in the 1970's but a cluster of deaths, later linked to the drug's risk of agranulocytosis, led to its withdrawal in most countries. However, work in the 1980's established its unique efficacy in treatment resistant schizophrenia (TRS), which constitutes as...

journal_title：Expert opinion on drug safety

authors： Remington G,Lee J,Agid O,Takeuchi H,Foussias G,Hahn M,Fervaha G,Burton L,Powell V

更新日期：2016-09-01 00:00:00

abstract：:Bone morphogenetic proteins (BMPs) have been extensively studied since the discovery of agents within bone that could induce bone formation at ectopic sites by Urist in the 1960s. Extensive preclinical research has been carried out showing the efficacy of these products in promoting bone healing. Clinical trials are e...

journal_title：Expert opinion on drug safety

authors： Harwood PJ,Giannoudis PV

更新日期：2005-01-01 00:00:00

abstract：INTRODUCTION:Acne is a common skin condition of the pilosebaceous units that affects the young and old, ranges from moderate to severe and can be treated with an array of options. Topical retinoids are the initial treatment for acne due to their ability to treat comedones, the starting point of acne. AREAS COVERED:Taz...

journal_title：Expert opinion on drug safety

authors： Smith JA,Narahari S,Hill D,Feldman SR

更新日期：2016-01-01 00:00:00

abstract：:Folic acid supplementation has drawn much attention in recent years for the prevention of Alzheimer's disease and cognitive decline. In this review, the authors describe how current evidence does not support the use of folic acid supplements to protect against cognitive decline. Although a few studies suggest that fol...

journal_title：Expert opinion on drug safety

authors： Schneider JA,Tangney CC,Morris MC

更新日期：2006-07-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Bisphosphonates are the most widely used antiresorptive agents for the treatment of osteoporosis. However, the cumulative bisphoshonate exposure and its association with atypical fragility fractures, and the optimum duration of treatment remain obscure. AREAS COVERED IN THIS REVIEW:This review ...

journal_title：Expert opinion on drug safety

authors： Charopoulos I,Orme S,Giannoudis PV

更新日期：2011-01-01 00:00:00

abstract：INTRODUCTION:Oral antidiabetic medications are important in many type 2 diabetes care plans. AREAS COVERED:The article summarizes the cardiovascular and renal safety data for DPP-4 inhibitors and SGLT-2 inhibitors and specific safety data particular to each class. EXPERT OPINION:DPP-4 and SGLT-2 inhibitors provide un...

journal_title：Expert opinion on drug safety

authors： Lamos EM,Hedrington M,Davis SN

更新日期：2019-08-01 00:00:00

abstract：:Introduction: Botulinum toxin (BoNT) is a protein secreted by the anaerobic Gram-negative bacterium Clostridium botulinum. Among the seven known subtypes, type A is the most commonly used in women to treat diseases. It primarily blocks presynaptic release of acetylcholine at the neuromuscular junction, resulting in te...

journal_title：Expert opinion on drug safety

authors： Li W,Tang M

更新日期：2020-01-01 00:00:00

abstract：:Objectives: Bullous pemphigoid, an autoimmune dermatological disease, may be associated with the use of a relatively new anti-cancer drug class, PD-1 inhibitors, which includes pembrolizumab and nivolumab. This paper analyzes the signals between PD-1 inhibitors and bullous pemphigoid based upon the reported real-world...

journal_title：Expert opinion on drug safety

authors： Aggarwal P

更新日期：2019-07-01 00:00:00

abstract：:Ixabepilone is a semisynthetic analogue of epothilone B, a novel microtubule-stabilizing agent. Preclinical data suggest that its mechanisms of actions are different from those of the most commonly used microtubule-stabilizing agent, paclitaxel. This information in addition to the cytotoxicity of this drug in taxane-r...

journal_title：Expert opinion on drug safety

authors： Gupta D,Mani S

更新日期：2009-01-01 00:00:00

abstract：INTRODUCTION:Development of new drugs in oncology may have implications for cardiovascular risk. This report describes some aspects of our growing knowledge in the area of evaluating benefit-risk and may be of direct importance to scientists working in drug discovery and development. AREAS COVERED:This report of webin...

journal_title：Expert opinion on drug safety

authors： Braddock M,Heilbraun J,Mendzelevski B

更新日期：2013-09-01 00:00:00

abstract：INTRODUCTION:Atrial fibrillation (AF) is a cause of significant morbidity and mortality. Catheter ablation for AF (CAAF) has emerged as an effective treatment option of rhythm control for patients with symptomatic AF. However, the risk of thromboembolism and bleeding in the periprocedural period represent a worrisome c...

journal_title：Expert opinion on drug safety

authors： Briceño DF,Madan N,Romero J,Londoño A,Villablanca PA,Natale A,Di Biase L

更新日期：2017-07-01 00:00:00

abstract：OBJECTIVE:Driven by the need of pharmacovigilance centres and companies to routinely collect and review all available data about adverse drug reactions (ADRs) and adverse events of interest, we introduce and validate a computational framework exploiting dominant as well as emerging publicly available data sources for d...

journal_title：Expert opinion on drug safety

authors： Koutkias VG,Lillo-Le Louët A,Jaulent MC

更新日期：2017-02-01 00:00:00

abstract：BACKGROUND:Clinical data on the long-term safety and efficacy of infliximab on psoriatic patients who are older than 65 years are limited. OBJECTIVES:The aim is to report the long-term efficacy, safety and tolerance of infliximab in geriatric patients. METHODS:This was a retrospective study conducted at the Departmen...

journal_title：Expert opinion on drug safety

authors： Chiricozzi A,Pavlidis A,Dattola A,Bianchi L,Chimenti MS,Fida M,Saraceno R

更新日期：2016-11-01 00:00:00

abstract：INTRODUCTION:Lanreotide autogel is a synthetic somatostatin analogue which has been FDA and EMA approved for unresectable, well to moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumor. Its action is mediated by its affinity to somatostatin receptors, especially sst2 and ...

journal_title：Expert opinion on drug safety

authors： Godara A,Siddiqui NS,Byrne MM,Saif MW

更新日期：2019-01-01 00:00:00

abstract：:The non-nucleoside analogue inhibitor of the reverse transcriptase, efavirenz (EFV), has become commonly used in highly active antiretroviral combination therapy in the treatment of HIV infection. Although being effective in suppressing plasma viral load, neuropsychiatric side effects have been reported in individuals...

journal_title：Expert opinion on drug safety

authors： Arendt G,de Nocker D,von Giesen HJ,Nolting T

更新日期：2007-03-01 00:00:00

abstract：INTRODUCTION:Mood stabilizer (MS) plus antipsychotic (AP) co-treatment is common in patients with acute bipolar disorder (BD), but adverse effects (AEs) of this strategy have not been systematically reviewed. AREAS COVERED:We conducted a systematic review searching PubMed/MEDLINE and PsycINFO on April 1, 2015 for rand...

journal_title：Expert opinion on drug safety

authors： Galling B,Garcia MA,Osuchukwu U,Hagi K,Correll CU

更新日期：2015-08-01 00:00:00

abstract：:Introduction: Patients living with schizophrenia have a marked risk of clinically significant weight gain and obesity compared to the general population. The risks have been highlighted following the introduction of second-generation antipsychotics. In turn, obesity is associated with a higher prevalence of cardiovasc...

journal_title：Expert opinion on drug safety

authors： Marteene W,Winckel K,Hollingworth S,Kisely S,Gallagher E,Hahn M,Ebdrup BH,Firth J,Siskind D

更新日期：2019-12-01 00:00:00

abstract：INTRODUCTION:Hyperhidrosis affects 4.8% of the U.S. population and has been underestimated by physicians for long time despite considerable interference with quality of life. Many patients suffer from primary (idiopathic) hyperhidrosis which results from over-activity of sympathetic nerves and is restricted to specific...

journal_title：Expert opinion on drug safety

authors： Hosp C,Hamm H

更新日期：2017-09-01 00:00:00

abstract：:Aspirin use is associated with gastroduodenal mucosal damage and increased risk of upper gastrointestinal (GI) bleeding. Many aspirin users should receive prophylactic treatment since they often have several risk factors for upper GI complications. The best therapeutic approach for reducing GI toxicity in low-dose asp...

journal_title：Expert opinion on drug safety

authors： Lanas A,Ferrández A

更新日期：2002-09-01 00:00:00

abstract：INTRODUCTION:Cardiovascular disease remains the major contributor to morbidity and mortality in diabetes. From the need to reduce cardiovascular risk in diabetes and to ensure that such risk is not exacerbated by drug treatments, governmental regulators and drug manufacturers have focused on clinical trials evaluating ...

journal_title：Expert opinion on drug safety

authors： Younk LM,Lamos EM,Davis SN

更新日期：2016-09-01 00:00:00

abstract：:The use of warfarin in the elderly, particularly for stroke prevention in chronic atrial fibrillation, is steadily increasing. Although the benefits of warfarin are greatest in the elderly, so are the risk of adverse outcomes and the difficulties of anticoagulant management. Clinical systems need to improve to counter...

journal_title：Expert opinion on drug safety

authors： Bereznicki LR,Peterson GM,Jackson SL,Jeffrey EC

更新日期：2006-05-01 00:00:00

abstract：:Introduction: Rucaparib is increasingly being utilized for women with recurrent ovarian cancer both as treatment and maintenance therapy. Poly-ADP ribose polymerase (PARP) inhibitors like rucaparib are daily oral medication that exploit the DNA repair pathway. The most significant clinical benefit is in those tumors e...

journal_title：Expert opinion on drug safety

authors： Cosgrove CM,O'Malley DM

更新日期：2018-12-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Clopidogrel is an antiplatelet prodrug widely used in acute coronary syndromes and after intravascular stent placement. Acute or chronic use can cause bleeding, a major adverse effect, which can lead to drug discontinuation or noncompliance with therapy. AREAS COVERED IN THIS REVIEW:The mechani...

journal_title：Expert opinion on drug safety

authors： Mangalpally KK,Kleiman NS

更新日期：2011-01-01 00:00:00

abstract：INTRODUCTION:Secondary preventative therapies are essential for patients undergoing coronary artery bypass graft (CABG) surgery to optimize perioperative and long-term outcomes. Beta-blockers are commonly used to treat patients with coronary artery disease and congestive heart failure (CHF), but their role for CABG pat...

journal_title：Expert opinion on drug safety

authors： Thaper A,Kulik A

更新日期：2018-08-01 00:00:00

abstract：INTRODUCTION:Despite the significant advances in the pharmacological and interventional management of patients with cardiovascular disease (CVD) over the last decades, cardiovascular mortality remains the leading cause of death. Large randomized clinical trials have investigated the efficacy and safety of different ant...

journal_title：Expert opinion on drug safety

authors： Romano S,Buccheri S,Mehran R,Angiolillo DJ,Capodanno D

更新日期：2018-10-01 00:00:00

abstract：:Osteonecrosis of the jaw is a new disease, partly caused by bisphosphonates. It is commonly assumed that the bisphosphonates somehow cause cell death (osteocyte necrosis) within the jawbone, which makes it prone to chronic infection. In this article, an alternative pathogenetic theory is suggested, based on the normal...

journal_title：Expert opinion on drug safety

authors： Aspenberg P

更新日期：2006-11-01 00:00:00

abstract：INTRODUCTION:A growing number of children globally are being treated for multidrug-resistant tuberculosis (MDR-TB). The second-line injectable antituberculosis medications amikacin, kanamycin and capreomycin, traditionally a mainstay of MDR-TB treatment, cause important adverse effects including permanent sensorineural...

journal_title：Expert opinion on drug safety

authors： Garcia-Prats AJ,Schaaf HS,Hesseling AC

更新日期：2016-11-01 00:00:00